The company has a focus on the discovery and clinical development of biomedical drugs, with antibody discovery platforms that accelerate the discovery and development of antibody drugs for cardiovascular diseases, tumors, kidney diseases, and more. Biosion is committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. The company has built a pipeline of innovative biologics through its internally derived technologies, including the H³ antibody discovery, SynTracer™ HT-endocytosis, and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma, and the company plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China.